Lacosamida Tarbis (Lacosamide)

Lacosamide enhances the slow inactivation of voltage‑gated sodium channels in neurons, stabilizing hyperexcitable membranes and reducing repetitive firing. This mechanism diminishes neuronal hyperexcitability that underlies seizure generation, providing antiepileptic effects without markedly affecting normal neuronal conduction.

The dosage of Lacosamida Tarbis is determined by the prescribing clinician based on the patient’s clinical condition, age, renal function, and concomitant therapies. The prescriber will select an appropriate intravenous dosing regimen and adjust it as needed.

Safety of lacosamide in pregnancy and lactation has not been fully established. It should be used only if the potential benefit justifies the potential risk to the fetus. Breastfeeding mothers should discuss possible exposure with their healthcare provider.

To request Lacosamida Tarbis, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Lacosamide’s unique mechanism—enhancing slow sodium‑channel inactivation—differs from many traditional antiepileptics that target fast inactivation. This can provide additive seizure control when combined with other agents, and it may have a lower risk of certain drug‑drug interactions compared with enzyme‑inducing antiepileptics.

Lacosamida Tarbis should be stored at ambient temperature, preferably below 25 °C, in its original packaging. Protect the solution from light and moisture, and keep it out of reach of children. Do not freeze the product.

The product is supplied as an intravenous solution and is administered by slow infusion into a vein under medical supervision. The infusion rate and duration are set by the treating physician according to the patient’s clinical needs.

Serious risks include cardiac conduction abnormalities such as PR‑interval prolongation, severe skin reactions like Stevens‑Johnson syndrome, and emergence of suicidal thoughts or depressive symptoms. Patients should be monitored for these events, especially during treatment initiation or dose changes.

Patients with known hypersensitivity to lacosamide or any component of the formulation should avoid the product. Caution is also advised for individuals with significant cardiac conduction disorders, severe hepatic impairment, or uncontrolled renal disease, where alternative therapies may be preferred.